For some reason which my tired brain can't figure out, this will only type in italics, bold or underlined. I figured that italics shouted less!
Phylomer peptides as target validation tools for Cryptosporidium are the focus of a newly published study in Experimental Parasitology (January 2015). The study was funded by Phylogica and the ARC Linkage Grant. Research was conducted by the School of Veterinary and Life Sciences, Murdoch University; Phylogica, Telethon Institute for Child Health Research and the School of Population Health, University of Queensland.
The Phylomer screening approach used in the study was reported to have yielded a relatively high functional hit rate. The authors also reported successful validation of the concept that cell penetrating motifs such as TAT can be used to deliver therapeutic Phylomer cargoes inside cells.
The authors note in conclusion
“
“
Phylomers have enormous potential as target validation tools for Cryptosporidium and other organisms and diseases because they are able to bind with high affinity to target proteins and disrupt function.”
Cryptosporidium is the most common non-viral cause of diarrhoea worldwide. It most severely impacts young children and the immunocompromised but is also a problem in the livestock and poultry industries. The small-sized parasite is resistant to most known disinfectants and current treatment options are limited.
http://www.sciencedirect.com/science/article/pii/S001448941400246X
http://researchrepository.murdoch.edu.au/24790/1/inosine_monophosphate_dehydrogenase_gene.pdf
- Forums
- ASX - By Stock
- PYC
- Published paper re phylomer peptides
PYC
pyc therapeutics limited
Add to My Watchlist
0.40%
!
$1.27

Published paper re phylomer peptides
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$1.27 |
Change
0.005(0.40%) |
Mkt cap ! $740.7M |
Open | High | Low | Value | Volume |
$1.27 | $1.29 | $1.27 | $406.0K | 319.3K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 13987 | $1.27 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.29 | 1380 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 13987 | 1.265 |
1 | 15000 | 1.260 |
1 | 12000 | 1.255 |
1 | 4000 | 1.225 |
1 | 20000 | 1.220 |
Price($) | Vol. | No. |
---|---|---|
1.290 | 25630 | 2 |
1.295 | 24500 | 1 |
1.300 | 59168 | 4 |
1.325 | 9001 | 1 |
1.330 | 20000 | 2 |
Last trade - 16.10pm 27/06/2025 (20 minute delay) ? |
Featured News
PYC (ASX) Chart |
The Watchlist
PAR
PARADIGM BIOPHARMACEUTICALS LIMITED..
Paul Rennie, MD & Founder
Paul Rennie
MD & Founder
SPONSORED BY The Market Online